| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acknowledgments
|
|
|
|
8 |
1S3 |
p.
|
article
|
| 2 |
Editorial Board
|
|
|
|
8 |
1S3 |
p.
|
article
|
| 3 |
European Society for Medical Oncology (ESMO)
|
|
|
|
8 |
1S3 |
p.
|
article
|
| 4 |
47MO Activating EZH2 mutations define a new subset of aggressive Ewing sarcomas
|
Sobczuk, P.
|
|
|
8 |
1S3 |
p.
|
article
|
| 5 |
124MO A single centre experience of patients with rare cancers referred for early phase clinical trials
|
Angelakas, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 6 |
49MO Atezolizumab and bevacizumab in patients treated with prior atezolizumab in alveolar soft tissue sarcoma (ASPS)
|
Chen, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 7 |
48MO Characteristics and outcomes of 76 patients with pleomorphic liposarcoma: The Gustave Roussy experience
|
Assi, T.S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 8 |
29MO Germline variants NGS characterization in patients with non-syndromic adrenocortical carcinoma
|
Grisanti, S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 9 |
28MO Predictive biomarkers of response to axitinib in patients with advanced EP-NETs enrolled in the AXINET trial (GETNE 1107): Underlying molecular mechanisms
|
Lens-Pardo, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 10 |
Notice and Disclaimer
|
|
|
|
8 |
1S3 |
p.
|
article
|
| 11 |
42O A phase Ia/b, dose-escalation and expansion study evaluating the MDM2–p53 antagonist BI 907828 in patients with solid tumours: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)
|
Schoeffski, P.
|
|
|
8 |
1S3 |
p.
|
article
|
| 12 |
45O Clonal evolution of dedifferentiated liposarcoma
|
Sekita, T.
|
|
|
8 |
1S3 |
p.
|
article
|
| 13 |
44O Comparison of clinical outcomes of patients with infantile fibrosarcoma (IFS) treated with larotrectinib in the SCOUT study versus historical cohort: The EPI-VITRAKVI study
|
Orbach, D.
|
|
|
8 |
1S3 |
p.
|
article
|
| 14 |
13O Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients: A TMRG and GINECO group study
|
Hanvic, B.
|
|
|
8 |
1S3 |
p.
|
article
|
| 15 |
46O Integrated molecular analysis of human dedifferentiated liposarcoma identifies a population of tumoral progenitors vulnerable to TGF beta inhibition
|
Watson, S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 16 |
27O Master gene regulation activity and methylation data reveals common patterns in well differentiated neuroendocrine tumors (NETs) from different tumor sites
|
Carretero-Puche, C.
|
|
|
8 |
1S3 |
p.
|
article
|
| 17 |
43O MDM2 inhibitor milademetan: Safety profile and management of adverse events (AEs)
|
Fabbroni, C.
|
|
|
8 |
1S3 |
p.
|
article
|
| 18 |
8O Outcomes for patients with appendix adenocarcinoma and the role of systemic chemotherapy
|
Strach, M.C.
|
|
|
8 |
1S3 |
p.
|
article
|
| 19 |
22O Sinonasal cancer: Molecular biomarkers for tumor classification and targeted treatment
|
Hermsen, M.A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 20 |
41P Addressing the unmet need for salivary gland cancers in the UK and beyond
|
Kinloch, E.
|
|
|
8 |
1S3 |
p.
|
article
|
| 21 |
96P Age-adjusted trends and survival analysis of alveolar soft part sarcoma
|
Aly, A.S.E.S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 22 |
103P Analysis of resected liposarcoma tumors identifies CD73 as a potential therapeutic target
|
Oliva Ramirez, J.
|
|
|
8 |
1S3 |
p.
|
article
|
| 23 |
111P A novel immune cell signature for predicting pleomorphic sarcoma prognosis
|
Gambale, E.
|
|
|
8 |
1S3 |
p.
|
article
|
| 24 |
113P ANZSA guideline on chemotherapy in primary resectable retroperitoneal sarcoma
|
Connolly, E.A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 25 |
112P A single-arm, open, multicenter study to evaluate pegylated liposomal doxorubicin in the treatment of osteosarcoma
|
Xu, H-R.
|
|
|
8 |
1S3 |
p.
|
article
|
| 26 |
20P A single-center retrospective analysis of clinical patterns, management and survival outcomes of malignant ovarian germ cell tumors
|
Tansir, G.
|
|
|
8 |
1S3 |
p.
|
article
|
| 27 |
3P Bevacizumab plus irinotecan as second-line treatment of glioblastoma: Real-world evidence
|
Ranchor, R.
|
|
|
8 |
1S3 |
p.
|
article
|
| 28 |
30P Bone fragility in patients with adrenocortical carcinoma undergoing mitotane therapy
|
Cosentini, D.
|
|
|
8 |
1S3 |
p.
|
article
|
| 29 |
31P Bone metastases and skeletal related events in pheochromocytoma and paraganglioma patients: International, retrospective study
|
Laganà, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 30 |
95P Cardiac sarcoma: Impact of adjuvant chemotherapy versus adjuvant radiotherapy on survival outcome
|
Elserry, A.M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 31 |
26P Characterization of a unique immortal tumor cell line as preclinical model for sinonasal teratocarcinosarcoma
|
Hermsen, M.A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 32 |
110P Characterization of miRNA-mRNA network in soft tissue sarcoma
|
Pillozzi, S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 33 |
1P Clinical characteristics and treatment outcomes for adult medulloblastoma: A tertiary cancer center experience
|
Erjan, A.A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 34 |
82P Clinical impact of systematic next generation sequencing in bone and soft-tissue sarcomas: Experience of a Spanish reference center
|
Arregui Valles, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 35 |
15P Clinicopathological characteristics and survival outcomes for PTSS and ETT: A population-based study
|
Alshwayyat, S.A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 36 |
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas
|
Strizova, Z.
|
|
|
8 |
1S3 |
p.
|
article
|
| 37 |
126P Comprehensive efforts to address multifaceted issues of rare cancers and sarcomas in Japan
|
Kawai, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 38 |
65P Continued improvement in overall survival from extremity soft tissue sarcoma over 28 years
|
El Sayed, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 39 |
129P Denosumab treatment in adults with metastatic, unresectable or resectable high-risk primary giant cell tumor of bone: Real-life cohort
|
Yildirim, H.C.
|
|
|
8 |
1S3 |
p.
|
article
|
| 40 |
67P Detrimental effect of the COVID-19 pandemic on patients with adult extremity bone sarcoma: Reference center experience
|
Teterycz, P.
|
|
|
8 |
1S3 |
p.
|
article
|
| 41 |
62P Digital narrative diary: The role in daily clinical practice of soft tissue and bone sarcomas patients
|
Buccilli, D.
|
|
|
8 |
1S3 |
p.
|
article
|
| 42 |
71P Does age impact outcomes of osteosarcoma? A single-center retrospective evaluation of the demographic profile and outcome of osteosarcoma in patients more than 40 years of age
|
Bhargava, P.G.
|
|
|
8 |
1S3 |
p.
|
article
|
| 43 |
78P Dose-dense epirubicin and cisplatin (ddEP) in localised osteosarcoma
|
Thomas, Z.
|
|
|
8 |
1S3 |
p.
|
article
|
| 44 |
9P Epidemiology and characteristics of fibrolamellar hepatocellular carcinoma: An analysis of surveillance, epidemiology, and end results (SEER) database
|
Elfaituri, M.K.
|
|
|
8 |
1S3 |
p.
|
article
|
| 45 |
58P Evaluating the impact of WGTS in routine diagnostics of bone and soft tissue tumors
|
Wallander, K.M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 46 |
54P Evaluation with FDG-PET during pretreatment of gastrointestinal stromal tumour, GIST, with imatinib
|
Lindskog, S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 47 |
89P EWSR1-PATZ1 fusion malignancies with completely different clinic histopathological behaviors
|
Kuo, Y-J.
|
|
|
8 |
1S3 |
p.
|
article
|
| 48 |
80P Expanded access program use of ripretinib in advanced GIST patients in the United Kingdom
|
Napolitano, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 49 |
17P Exploiting the immune-modulatory effects of PI3K/mTOR inhibitors to enhance response to immune-checkpoint blockade in uterine leiomyosarcoma
|
De Wispelaere, W.
|
|
|
8 |
1S3 |
p.
|
article
|
| 50 |
7P Extracranial metastasis of CNS malignancies and medulloblastomas in particular in adult patients with a ventriculoperitoneal shunt: Review of the literature
|
Mentesidou, V.
|
|
|
8 |
1S3 |
p.
|
article
|
| 51 |
4P FAT1: A novel modulator of autophagy in human glioblastoma
|
Gupta, Y.
|
|
|
8 |
1S3 |
p.
|
article
|
| 52 |
35P Feasibility and activity of megestrol acetate in addition to EDP-M as first-line therapy in patients with metastatic/unresectable adrenocortical carcinoma
|
Turla, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 53 |
99P Fibroblast activation protein alpha (FAP) as theranostic target in solitary fibrous tumor
|
Hamacher, R.W.
|
|
|
8 |
1S3 |
p.
|
article
|
| 54 |
63P Gastrointestinal stromal tumours in the imatinib era: Outcomes of a treatment and follow-up programme in Western Sweden from 2004-2020
|
Berndsen, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 55 |
34P Genomic profiling of NEN patients: Prognostic and therapeutic relevance
|
Antón Pascual, B.
|
|
|
8 |
1S3 |
p.
|
article
|
| 56 |
79P Ifosfamide neurotoxicity in sarcoma patients: A real-life analysis from a sarcoma referral centre
|
Chiavassa, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 57 |
128P Impact of an online educational activity on oncologists’ knowledge regarding the latest developments in the treatment of uveal melanoma
|
Dorkhom, N.
|
|
|
8 |
1S3 |
p.
|
article
|
| 58 |
122P Impact of surgical management in improving the quality of life in patients diagnosed with Marjolin's ulcer: A prospective observational study from a tertiary care center in India
|
Irrinki, R.N.N.S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 59 |
118P Influence of tumor immune infiltrate characteristics on survival rates of patients with choroid melanoma
|
Zherka, I.
|
|
|
8 |
1S3 |
p.
|
article
|
| 60 |
59P Introducing liquid biopsy for paediatric sarcoma patients into the clinical routine
|
Leithner, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 61 |
86P Kaposi's sarcoma: A single-institution experience
|
Pessoa, D.C.O.M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 62 |
2P Long-term follow-up to the phase I/II study of CAN008 plus standard chemoradiotherapy treatment in patients with newly diagnosed glioblastoma multiforme
|
Chang, I.Y-F.
|
|
|
8 |
1S3 |
p.
|
article
|
| 63 |
5P Long term outcome of surgical management for vertebral hemangioma presenting with myelopathy
|
Singh, P.K.
|
|
|
8 |
1S3 |
p.
|
article
|
| 64 |
52P Long-term outcomes in children, adolescents, and young adults with localized Ewing sarcoma treated with standard vs dose-intensified ifosfamide
|
Kinnaman, M.D.
|
|
|
8 |
1S3 |
p.
|
article
|
| 65 |
119P Long-term safety evaluation of roginolisib (formerly IOA-244), a highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study
|
Di Giacomo, A.M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 66 |
19P Long term sexual disorders among rare ovarian cancer survivors: The national GINECO case-control Vivrovaire Rare Tumors study
|
Dubot, C.
|
|
|
8 |
1S3 |
p.
|
article
|
| 67 |
18P Malignant Brenner ovarian tumor: Fertility-sparing surgery versus radical hysterectomy
|
Ellaithy, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 68 |
92P Management and treatment outcomes of malignant retroperitoneal tumors following resection: Experience of a tertiary care center in Pakistan
|
Virji, S.N.
|
|
|
8 |
1S3 |
p.
|
article
|
| 69 |
91P Management challenges of extremity sarcomas in under-resourced settings: The first survey-based study in Morocco
|
Kharmoum, S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 70 |
21P Medullary carcinoma of the breast: About 18 cases
|
Bettaieb, O.
|
|
|
8 |
1S3 |
p.
|
article
|
| 71 |
117P Merkel cell carcinoma: Epidemiological pattern in the United States, a SEER based study
|
Elsayed, M.A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 72 |
97P Modern outcomes with re-irradiation, systemic therapy and surgery for radiotherapy-associated angiosarcoma of the breast
|
Asha, W.A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 73 |
72P Molecular characterization of advanced primary cardiac sarcomas
|
Agostara, A.G.
|
|
|
8 |
1S3 |
p.
|
article
|
| 74 |
10P Molecular mutations in appendix cancers
|
Strach, M.C.
|
|
|
8 |
1S3 |
p.
|
article
|
| 75 |
104P Multi-omic profiling and real-time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation
|
Chan, J.Y.
|
|
|
8 |
1S3 |
p.
|
article
|
| 76 |
39P Neuroendocrine neoplasms: A retrospective analysis in a single Algerian institution
|
Belabdi, D.
|
|
|
8 |
1S3 |
p.
|
article
|
| 77 |
108P New biomarkers in liposarcomas: A metabolic approach
|
Bouillin, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 78 |
68P Optimization of giant cell tumor treatment: First Russian big data
|
Tararykova, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 79 |
53P Oral metronomic-continuous cyclophosphamide (MCy) for elderly or unfit patients with advanced soft tissue sarcoma (STS): Reina Sofía University Hospital experience
|
Moreno Vega, A.L.
|
|
|
8 |
1S3 |
p.
|
article
|
| 80 |
55P Our experience of the hormone therapy in uterine sarcoma patients
|
Kovalchuk, V.
|
|
|
8 |
1S3 |
p.
|
article
|
| 81 |
51P Outcomes of adult patients undergoing extrapleural pneumonectomy for sarcoma at a specialised centre
|
Zhang, B.
|
|
|
8 |
1S3 |
p.
|
article
|
| 82 |
127P Outcomes of advanced chordoma from dedicated sarcoma medical oncology clinic from a tertiary care center in North India
|
Rastogi, S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 83 |
6P Patterns of treatment of patients with glioblastoma multiforme in the real world, a Mexican experience
|
Trejo Rosales, R.R.
|
|
|
8 |
1S3 |
p.
|
article
|
| 84 |
61P Pazopanib in the real-world setting: Data from the Italian national registry
|
Mazzocca, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 85 |
56P Pembrolizumab in advanced mesenchymal tumors: A prospective monocentric study
|
Cremante, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 86 |
101P Pharmacological inhibition of glyoxalase-1 as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models
|
Vincenzi, B.
|
|
|
8 |
1S3 |
p.
|
article
|
| 87 |
33P Pheochromocytoma during pregnancy in Sweden from 1973-2015: Short and long-term outcome
|
Gunnesson, L.
|
|
|
8 |
1S3 |
p.
|
article
|
| 88 |
120P Pigmentation level of uveal melanoma and its development
|
Sopel, J.
|
|
|
8 |
1S3 |
p.
|
article
|
| 89 |
84P Post-radiation sarcomas: A real-life analysis from a referral centre
|
Veroli, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 90 |
130P Primary cilium (PC) associated BBSome gene expression profile during oxidative stress in 2D and 3D culture models of mesothelial cells
|
Jagirdar, R.M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 91 |
88P Primary malignant bone sarcomas: Experience of a Portuguese referral center
|
Ranchor, R.
|
|
|
8 |
1S3 |
p.
|
article
|
| 92 |
75P Primary sarcomas of gastrointestinal tract: A single-institution experience of a rare entity
|
Khosla, D.
|
|
|
8 |
1S3 |
p.
|
article
|
| 93 |
73P Proton radiotherapy in treatment of desmoid tumors
|
Lipanova, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 94 |
83P Radiological evaluation of response in patients with soft tissue sarcoma treated with trabectedin
|
Ceddia, S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 95 |
25P RC48-ADC for metastatic salivary duct carcinoma with HER2-expression: A single-center retrospective study
|
Cao, J.
|
|
|
8 |
1S3 |
p.
|
article
|
| 96 |
93P Reduced malignancy of super methotrexate-resistant osteosarcoma cells is linked to elevated expression of PI3K/AKT/mTOR and c-MYC
|
Aoki, Y.
|
|
|
8 |
1S3 |
p.
|
article
|
| 97 |
12P Renal cancer metastasis patterns and racial disparities: SEER database population study 2010-2019
|
El-Sakka, A.A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 98 |
36P Response to peptide receptor radionuclide therapy in pheocromocytomas and paragangliomas: A systematic review and meta-analysis
|
Marretta, A.L.
|
|
|
8 |
1S3 |
p.
|
article
|
| 99 |
16P Response to taxanes in low-grade serous ovarian cancer patients and cell lines
|
Kumari, S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 100 |
94P Retroperitoneal sarcoma: Impact of adjuvant chemo(radio)therapy on survival outcome compared to the standard surgical resection with no systemic therapy
|
Ellaithy, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 101 |
87P Rhabdomyosarcoma in adult patients: Management in a high-volume Spanish sarcoma center
|
Buezas, R.
|
|
|
8 |
1S3 |
p.
|
article
|
| 102 |
85P Ripretinib dose escalation after disease progression for Chinese patients with advanced gastrointestinal stromal tumor: A multi-center retrospective analysis
|
Zhou, Y.
|
|
|
8 |
1S3 |
p.
|
article
|
| 103 |
98P Safety and toxicity of mifamurtide treatment in patients with osteosarcoma: A single-center experience
|
Manisterski, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 104 |
105P SFX-01 in the treatment of rhabdomyosarcoma: Preclinical results in cellular models
|
Camero, S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 105 |
125P Sirolimus experience in adult patients with vascular anomalies
|
Yildirim, H.C.
|
|
|
8 |
1S3 |
p.
|
article
|
| 106 |
81P Soft tissue solitary fibrous tumor: Analysis of a single center series with a comparison between three prognostic scores
|
Scoccianti, G.
|
|
|
8 |
1S3 |
p.
|
article
|
| 107 |
37P Survival and prognostic factors in appendiceal neuroendocrine tumours and goblet cell carcinoma
|
Dijke, K.
|
|
|
8 |
1S3 |
p.
|
article
|
| 108 |
106P Synergistic effect of CDK4/6 inhibitors and standard chemotherapy sequential treatment on liposarcoma patient-derived primary culture
|
Vanni, S.
|
|
|
8 |
1S3 |
p.
|
article
|
| 109 |
121P Temozolomide plus cisplatin as first-line treatment for advanced or metastatic mucosal melanoma
|
Aldaco Sarvide, F.
|
|
|
8 |
1S3 |
p.
|
article
|
| 110 |
64P Tertiary lymphoid structure and efficacy of doxorubicin in patients with soft tissue sarcoma: The Centre Léon Bérard experience
|
Grassi, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 111 |
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma
|
Schreck, C.
|
|
|
8 |
1S3 |
p.
|
article
|
| 112 |
60P The diagnostic pathway of sarcoma patients: Results from the QUEST study in the Netherlands and the United Kingdom: A cohort study
|
Holthuis, E.
|
|
|
8 |
1S3 |
p.
|
article
|
| 113 |
66P Therapeutic opportunities in sarcomas and rare tumors: What path for antibody-drug conjugates?
|
Vanacker, H.
|
|
|
8 |
1S3 |
p.
|
article
|
| 114 |
32P The result of radiotherapy (RT) in patients with parathyroid carcinoma (PC): Experience of National Research Institute of Oncology in Poland, Gliwice Branch (NRIO)
|
Gawkowska, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 115 |
76P Thoracic synovial sarcoma: A single-center, real-world analysis of treatment paradigms and clinical outcomes
|
Tansir, G.
|
|
|
8 |
1S3 |
p.
|
article
|
| 116 |
123P Thymic neoplasms in Bavaria between 2002 and 2016: Has there been progress?
|
Bley, M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 117 |
70P Total neoadjuvant vs standard perioperative cisplatin/doxorubicin chemotherapy in patients with extremities osteosarcoma: A single-center cohort study
|
Javadinia, S.A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 118 |
24P TPD54 as a candidate biomarker for distant metastasis prediction in non-endemic nasopharyngeal carcinoma: Label-free quantitative proteomics results
|
Netto, E.
|
|
|
8 |
1S3 |
p.
|
article
|
| 119 |
69P Trabectedin rechallenge for the treatment of adults with advanced soft tissue sarcoma (STS): A pilot study (Re-Trabe)
|
Badalamenti, G.
|
|
|
8 |
1S3 |
p.
|
article
|
| 120 |
102P Transcriptomic and enhancer landscape profiling identify Src-family kinase LYN as a candidate therapeutic target in human angiosarcoma
|
Chan, J.Y.
|
|
|
8 |
1S3 |
p.
|
article
|
| 121 |
23P Treatment outcomes in nasal cavity and paranasal sinus tumors treated with postoperative volumetric modulated arc therapy
|
Bahl, A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 122 |
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib
|
Okita, Y.
|
|
|
8 |
1S3 |
p.
|
article
|
| 123 |
109P Unraveling homologous recombination deficiency and therapeutic opportunities in soft tissue and bone sarcoma
|
Planas-Paz, L.
|
|
|
8 |
1S3 |
p.
|
article
|
| 124 |
14P Unravelling the immune landscape of non-epithelial ovarian cancer
|
Laga, T.
|
|
|
8 |
1S3 |
p.
|
article
|
| 125 |
90P Virtual sarcoma disease multidisciplinary team: A jump into the future?
|
Salvatori, F.
|
|
|
8 |
1S3 |
p.
|
article
|
| 126 |
77P 5-year results of cytoreductive surgery in peritoneal and retroperitoneal sarcomatosis
|
Ozcan, P.
|
|
|
8 |
1S3 |
p.
|
article
|
| 127 |
Table of Contents
|
|
|
|
8 |
1S3 |
p.
|
article
|
| 128 |
40TiP Activity of the addition of progesterone to standard EDP-M scheme in patients with advanced adrenocortical carcinoma: A randomized, placebo-controlled phase II trial (PESETA)
|
Cremaschi, V.
|
|
|
8 |
1S3 |
p.
|
article
|
| 129 |
116TiP A phase I/II study of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced sarcoma including undifferentiated pleomorphic sarcoma
|
Wilky, B.
|
|
|
8 |
1S3 |
p.
|
article
|
| 130 |
132TiP Double-blind placebo-controlled trial of AL102 for treatment of progressing desmoid tumors (DT): The RINGSIDE phase III study design
|
Kasper, B.
|
|
|
8 |
1S3 |
p.
|
article
|
| 131 |
131TiP Measuring health-related quality of life in solid rare cancer patients: A study protocol
|
Simões Padilla, C.
|
|
|
8 |
1S3 |
p.
|
article
|
| 132 |
115TiP MYTH Study: Methotrexate for AYA in the home: A study of safety, feasibility, patient acceptability and cost effectiveness of an ambulatory model for AYA osteosarcoma patients
|
Connolly, E.A.
|
|
|
8 |
1S3 |
p.
|
article
|
| 133 |
114TiP Preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV-associated Kaposi sarcoma (StarKap)
|
Fulgenzi, C.A.M.
|
|
|
8 |
1S3 |
p.
|
article
|
| 134 |
Title Page
|
|
|
|
8 |
1S3 |
p.
|
article
|
Journal description